Contact
Please use this form to send email to PR contact of this press release:
Human medicines European public assessment report (EPAR): Rolufta Ellipta (previously Rolufta), umeclidinium, Date of authorisation: 20/03/2017, Revision: 12, Status: Authorised
TO: